Corbus Pharmaceuticals to present late-breaking CRB-913 Canyon-1 Phase 1B data at Obesity Week 2026

Corbus Pharmaceuticals will present late-breaking data from the CRB-913 Canyon-1 Phase 1B study at Obesity Week 2026.

Detected & updated continuously · Source: Nebula